Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial.
Fiche publication
Date publication
octobre 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AYAV Ahmet, Pr CONROY Thierry, Pr HARLE Alexandre, Dr LAMBERT Aurélien
Tous les auteurs :
Egea J, Salleron J, Gourgou S, Ayav A, Laurent V, Juzyna B, Harlé A, Conroy T, Lambert A
Lien Pubmed
Résumé
The follow-up of pancreatic cancer (PC) is based on computed tomography (CT) assessment; however, there is no consensus on the use of clinical and biological criteria in tumor progression. We aimed to establish a clinical-biological model to highlight the progression of metastatic PC during first-line treatment.
Mots clés
CA 19-9, pancreatic cancer, patient-reported outcomes, quality of life, tumor progression
Référence
Cancers (Basel). 2022 10 16;14(20):